Administration, Intranasal

• 

  Subject Areas on Research

  • A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. 
  • A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen. 
  • A computational study of functional endoscopic sinus surgery and maxillary sinus drug delivery. 
  • A novel neurotoxoid vaccine prevents mucosal botulism. 
  • Adenovirus F protein as a delivery vehicle for botulinum B. 
  • CaMKII is essential for the proasthmatic effects of oxidation. 
  • Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines. 
  • Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study. 
  • Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial. 
  • Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. 
  • Computed intranasal spray penetration: comparisons before and after nasal surgery. 
  • Contrasting response of lung parenchymal cells to instilled TNF alpha and IFN gamma: the inducibility of specific cell ICAM-1 in vivo. 
  • Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. 
  • Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. 
  • Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. 
  • Cytokines: the future of intranasal vaccine adjuvants. 
  • DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. 
  • Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity. 
  • Deviated nasal septum hinders intranasal sprays: a computer simulation study. 
  • Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination. 
  • Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1. 
  • Efficacy of intranasal corticosteroids for acute sinusitis. 
  • Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. 
  • Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins. 
  • Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV(89.6). 
  • Identification of early interactions between Francisella and the host. 
  • Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes. 
  • In vitro bioequivalence testing. 
  • Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes. 
  • Intranasal clonidine as a premedicant: three cases with unique indications. 
  • Intranasal fentanyl improves time to analgesic delivery in sickle cell pain crises. 
  • Intranasal fluticasone associated with delayed tympanostomy tube placement in children with eustachian tube dysfunction. 
  • Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. 
  • Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. 
  • Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. 
  • Intranasal vaccination with the recombinant Listeria monocytogenes ΔactA prfA* mutant elicits robust systemic and pulmonary cellular responses and secretory mucosal IgA. 
  • Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara. 
  • Lung injury, inflammation and Akt signaling following inhalation of particulate hexavalent chromium. 
  • Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. 
  • Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). 
  • Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. 
  • Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. 
  • Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. 
  • Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility. 
  • Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. 
  • Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. 
  • Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus. 
  • Nasal tetracaine spray-induced methemoglobinemia. 
  • Nasal vaccination with troponin reduces troponin specific T-cell responses and improves heart function in myocardial ischemia-reperfusion injury. 
  • Nicotine for postoperative analgesia: a systematic review and meta-analysis. 
  • Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. 
  • Novel intranasal pertussis vaccine based on bacterium-like particles as a mucosal adjuvant. 
  • Ozone inhalation promotes CX3CR1-dependent maturation of resident lung macrophages that limit oxidative stress and inflammation. 
  • Prevention of surgical-site infections. 
  • Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. 
  • Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women. 
  • Stable dry powder formulation for nasal delivery of anthrax vaccine. 
  • Study of the role of CCR5 in a mouse model of intranasal challenge with Yersinia pestis. 
  • The efficacy of isoproterenol inhalation for predicting the response to orally administered theophylline in chronic obstructive pulmonary disease. 
  • The misuse and diversion of prescribed ADHD medications by college students. 
  • Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. 
  • Treatment of hyperkalaemia using intravenous and nebulised salbutamol. 
  • Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques. 
  • Use of 1-desamino-8-D-arginine vasopressin in microsurgical reconstruction in a patient with von Willebrand's disease. 
• 

  Keywords of People

  • Gunn, Michael Dee, Professor of Medicine, Immunology